January 5, 2024 7:45am

VYGR closed up +$0.07 to $10.84 with a negative pre-open -$1.70 or -15.68% to $9.14

VYGR has commenced an underwritten public offering of 7.777,778 shares offering and 3,333,333 pre-funded warrants

Seeking $100 million before expenses ...

Citigroup and Guggenheim Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as book-running manager for the offering.

The Bottom Line:  an expected offering after license outcome ...

VYGR received $20.0 million from Novartis Pharma AG (Novartis) in January 2024 as consideration for the purchase of shares of its common stock.

An additional $80.0 million upfront payment anticipates receiving from Novartis in connection with the VYGR’s entry into a strategic collaboration and a stock purchase agreement with Novartis in December 2023,

… to advance its anti-tau antibody program for the treatment of Alzheimer’s disease (AD) and its SOD1 silencing gene therapy program for the treatment of amyotrophic lateral sclerosis (ALS) into clinical development, to advance its tau silencing gene therapy program for the treatment of AD and its anti-amyloid gene therapy program for the treatment of AD in preclinical development.


Market cap: $473.83 million

Enterprise value: $241.92 million

Cash: $252.94 million

Debt: $21.02 million

52-weekhigh – $14.34 and low of $5.89

50 day moving average: $7.34

200 day moving average: $8.84

Shares outstanding: 44 million

Float: 25.83 million

Short % of float (12/15/23): 4.86% and prior month: 1.92%

% owned by institutions: 60.94% and owned by insiders: 20.50%


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.